MECHANISM OF CISPLATIN OTOTOXICITY - ANTIOXIDANT SYSTEM

被引:259
作者
RAVI, R
SOMANI, SM
RYBAK, LP
机构
[1] SO ILLINOIS UNIV, SCH MED, DEPT PHARMACOL, SPRINGFIELD, IL 62794 USA
[2] SO ILLINOIS UNIV, SCH MED, DEPT SURG, SPRINGFIELD, IL 62794 USA
来源
PHARMACOLOGY & TOXICOLOGY | 1995年 / 76卷 / 06期
关键词
D O I
10.1111/j.1600-0773.1995.tb00167.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The dose and duration limiting toxic effects of cisplatin are ototoxicity and nephrotoxicity. While several studies have attempted to shed some light on the causes of nephrotoxicity, the reasons for ototoxicity induced by cisplatin are poorly understood. Therefore, this investigation was undertaken to delineate the potential mechanisms underlying cisplatin ototoxicity. The role of glutathione (GSH), oxidized glutathione (GSSG) and malondialdehyde levels, and antioxidant enzyme activities [superoxide dismutase, catalase, GSH peroxidase, and GSH reductase] were examined in cochlear toxicity following an acute dose of cisplatin. Male Wistar rats were treated with various doses of cisplatin. Pretreatment auditory brain stem evoked responses (ABR) were performed and then post-treatment ABRs and endocochlear potentials were also performed after three days. Acute cochlear toxicity (ototoxicity) was evidenced as elevated hearing thresholds and prolonged wave I latencies in response to various stimuli (clicks and tone bursts at 2, 8, 16 and 32 kHz) on ABRs. The endocochlear potentials were reduced (50% control) in cisplatin-treated rats as compared to control animals. The rats were sacrified and cochleae isolated. The GSH, GSSG and malondialdehyde levels, and antioxidant enzyme activities were determined. Cisplatin ototoxicity correlated with a decrease in cochlear GSH [0.45+/-0.012 nmol/mg] after cisplatin administration compared to 0.95+/-012 nmol/mg in control cochleae (P<0.05). Superoxide dismutase, catalase activities and malondialehyde levels were significantly increased in the cochleae of cisplatin injected rats. Cochlear GSH-peroxidase and GSH reductase activity significantly decreased after cisplatin administration. Alterations in the activity of antioxidant enzymes, an increase in malondialdehyde levels, and depletion of cochlear GSH suggest a role for reactive oxygen species mediated damage of the cochlea in cisplatin toxicity. These biochemical changes were accompanied by the elevation of ABR threshold that appears to correlate well with alterations in antioxidant systems which could be the cause of cisplatin ototoxicity.
引用
收藏
页码:386 / 394
页数:9
相关论文
共 70 条
  • [1] Aebi H., Catalase in vitro, Meth. Enzymol., 105, pp. 121-126, (1984)
  • [2] Barron S.E., Daigneault E.A., Effect of cisplatin on hair cell morphology and lateral wall Na‐K‐ATPase activity, Hear. Res., 26, pp. 131-137, (1987)
  • [3] Bompart G., Cisplatin‐induced changes in cytochrome P‐450, lipid peroxidation, and drug metabolizing enzyme activities in rat kidney cortex, Toxicol. Lett., 48, pp. 93-99, (1989)
  • [4] Boogaard P.J., Slikkerveer A., Nagelkerke J.F., Mulder G.J., The role of metallothionein in the reduction of cisplatin‐induced nephrotoxicity by Bi<sup>3+</sup> pretreatment in the rat in vivo and in vitro, Biochem. Pharmacol., 41, pp. 369-375, (1991)
  • [5] Bradford M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein‐dye binding, Anal. Biochem., 72, pp. 248-254, (1976)
  • [6] Brown R.D., Feldman A.M., Pharmacology of hearing and ototoxicity, Ann. Rev. Pharmacol. Toxicol., 18, pp. 233-252, (1978)
  • [7] Carlberg I., Mannervik B., Glutathione reductase, Meth. Enzymol., 113, pp. 484-490, (1985)
  • [8] Chiuten D., Vogle S.E., Kaplan B.H., Greenwald E., Is there a cumulative or delayed toxicity from cis‐diamminedichloroplatinum II (DDP), Proc. Amer. Assoc. Can. Res., 22, (1981)
  • [9] Cozzaglio L., Doci R., Colla G., Zunino F., Casciarri G., Gennari L., A feasibility study of high‐dose cisplatin and 5‐fluorouracil with GSH protection in the treatment of advanced colorectal cancer, Tumori, 76, pp. 590-594, (1990)
  • [10] Di Re F., Bohm S., Oriana S., Spatti G.B., Zunino F., Efficacy and safety of high‐dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer, Can. Chemother. Pharmacol., 25, pp. 355-360, (1990)